Component
Liver-specific AMPK-deficient mouse hepatocytes in the 2010 study
Liver-specific AMPK-deficient mouse hepatocytes in the 2010 study. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
In mice lacking AMPK in the liver, blood glucose was comparable to wild type and the hypoglycaemic effect of metformin was maintained; metformin-induced inhibition of glucose production was amplified in both AMPK- and LKB1-deficient hepatocytes.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/metformin-research/20577053.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14", "start_char": 0, "end_char": 1707, "text_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14"}
- experimental_model
- Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression
- exposure
- Metformin dose-response in hepatocytes lacking AMPK or LKB1
- limitations
- A direct challenge to the AMPK requirement. The measured correlate is intracellular ATP, so this is an energy-state mechanism rather than a signalling one.
- nutrient_topic
- Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin
- organism
- Mouse
- plain_language
- Removing the sensor did not remove the drug effect, and in these cells it made it larger.
- primary_references
- [metformin-p20577053] Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. (2010). https://pubmed.ncbi.nlm.nih.gov/20577053/ DOI: 10.1172/jci40671
- tissue_or_cell_type
- Liver
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 593–604
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression · source_derived_draft · unverified_draft
### metformin-ampk-independent-glucose In mice lacking AMPK in the liver, blood glucose was comparable to wild type and the hypoglycaemic effect of metformin was maintained; metformin-induced inhibition of glucose production was amplified in both AMPK- and LKB1-deficient hepatocytes. Condition category: machinery_impairment nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: Removing the sensor did not remove the drug effect, and in these cells it made it larger. organism: Mouse tissue_or_cell_type: Liver experimental_model: Liver-specific AMPK-deficient and LKB1-deficient mouse hepatocytes with PGC-1alpha overexpression limitations: A direct challenge to the AMPK requirement. The measured correlate is intracellular ATP, so this is an energy-state mechanism rather than a signalling one. exposure: Metformin dose-response in hepatocytes lacking AMPK or LKB1 evidence_span: {"source_cache": "artifacts/metformin-research/20577053.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14", "start_char": 0, "end_char": 1707, "text_sha256": "f6019de6b5a35f860f55b39d91656e5fd1077d34e301d244a1ea498b96faac14"} [metformin-p20577053] Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. (2010). https://pubmed.ncbi.nlm.nih.gov/20577053/ DOI: 10.1172/jci40671
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.